- Retroviruses copy RNA into DNA, reversing normal genetic flow.
- Temin and Baltimore discovered reverse transcriptase in 1970.
- Each replication step is a target for antiretroviral drugs.
The retrovirus replication cycle is the process by which retroviruses convert their RNA genome into DNA, integrate that DNA into a host cell's chromosomes, and use the cell's own machinery to produce new virus particles.
Why it matters
Key figure
1970
Year reverse transcriptase was discovered
Retroviruses broke one of biology's foundational rules. Before Howard Temin at the University of Wisconsin-Madison and David Baltimore at MIT independently discovered reverse transcriptase in 1970, the prevailing view held that genetic information flowed in one direction only: from DNA to RNA to protein. Francis Crick had codified this as the "central dogma" of molecular biology in 1958.
Retroviruses proved that RNA could be copied backward into DNA. That discovery earned Temin and Baltimore the Nobel Prize in Physiology or Medicine in 1975.
The finding opened two transformative fields. Antiretroviral drugs now target specific steps in the retrovirus replication cycle, turning HIV from a death sentence into a manageable chronic condition for millions of patients. Retroviral vectors, engineered from stripped-down retroviruses, deliver therapeutic genes directly into human cells. They were the first viral vectors used in a human gene therapy trial in 1990.
Roughly 8% of the human genome consists of endogenous retroviral sequences, remnants of ancient infections that became permanently woven into our DNA over millions of years. Some of these sequences have been co-opted for essential functions, including the formation of the placenta in mammals.
How the retrovirus replication cycle works
The cycle proceeds in six ordered steps. First, the virus binds to specific receptors on the host cell surface. The envelope protein on the virus recognizes and locks onto a matching receptor, then fuses with the cell membrane to release the viral RNA and enzymes into the cytoplasm.
Key figure
3
Enzymatic activities of reverse transcriptase
Once inside, reverse transcriptase performs three distinct enzymatic activities. It copies the single-stranded RNA into a complementary DNA strand using its RNA-dependent DNA polymerase function. It then degrades the original RNA template through its RNase H activity. Finally, it synthesizes the second DNA strand with its DNA-dependent DNA polymerase function, producing double-stranded viral DNA.
The viral enzyme integrase then inserts this DNA into the host cell's chromosomes, creating what virologists call a provirus. Howard Temin first proposed this provirus hypothesis in 1964, more than five years before the enzyme that made it possible was found.
Once integrated, the provirus is replicated along with the host cell's own DNA every time the cell divides. The host cell's transcription machinery reads the proviral DNA and produces new viral RNA and messenger RNA.
Ribosomes translate the messenger RNA into viral proteins, including structural proteins (Gag), enzymes (Pol), and envelope proteins (Env). These components assemble at the cell membrane, bud outward as new virus particles, and undergo a final maturation step where protease cleaves the polyproteins into their functional forms.
Key context
Each step of the replication cycle represents a potential drug target. The six FDA-approved classes of antiretroviral drugs used against HIV include reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors, entry inhibitors, fusion inhibitors, and pharmacokinetic enhancers. Combination therapy targeting multiple steps simultaneously is the basis of highly active antiretroviral therapy (HAART), introduced in 1996.
The discovery of reverse transcriptase also gave molecular biology one of its most important laboratory tools. Reverse transcriptase is essential for creating complementary DNA (cDNA) libraries and for RT-PCR, a technique used in everything from COVID-19 diagnostics to forensic science.
Peyton Rous at the Rockefeller Institute identified the first tumor-causing retrovirus in 1911 when he demonstrated that a filtered extract from a chicken sarcoma could transmit cancer to healthy birds. The mechanism remained unexplained for decades. Rous received his Nobel Prize in 1966, fifty-five years after the original discovery.
FAQ
How does a retrovirus differ from a regular virus?
Most viruses store their genetic information as either DNA or RNA and replicate it directly. Retroviruses are unique because they carry RNA but must convert it into DNA using reverse transcriptase before they can replicate. This extra step, reverse transcription, is what defines the family and gives it the name "retro," from the Latin for "backward."
Why is the retrovirus replication cycle so important for medicine?
Each step in the cycle is a potential target for antiviral drugs. The development of combination antiretroviral therapy, which attacks multiple steps simultaneously, transformed HIV from a fatal diagnosis into a treatable condition. The same cycle also provides the template for retroviral gene therapy vectors used to treat genetic diseases.
Can retroviruses cause cancer?
Yes. Some retroviruses, known as oncoretroviruses, can insert their DNA near or within genes that regulate cell growth. This insertional mutagenesis can activate oncogenes or disrupt tumor suppressor genes. Peyton Rous at the Rockefeller Institute identified the first tumor-causing retrovirus in 1911.
What percentage of the human genome comes from retroviruses?
About 8% of human DNA consists of endogenous retroviral sequences, remnants of infections that occurred millions of years ago. These sequences became fixed in the genome when retroviruses infected germ cells and the proviral DNA passed to offspring. Some of these ancient viral genes now serve essential biological functions.
Sources
- Primary Reference: Retroviruses (Coffin, Hughes, Varmus, 1997, Cold Spring Harbor Laboratory Press)
- Additional Context:
- Reverse Transcriptase and the Generation of Retroviral DNA (NCBI Bookshelf)
- Retroviruses: Structure, Replication and Applications (Danaher Life Sciences)
- Therapeutic Applications of Retroviruses (NCBI Bookshelf)
Fact Check: Claim-by-Claim Verification Verified
All major claims verified against authoritative sources. Core facts about reverse transcriptase discovery (1970), Nobel Prize (1975), provirus hypothesis (1964), RT enzymatic activities, endogenous retroviral DNA (~8%), and first gene therapy trial (1990) are well-established consensus science.
Sources used for verification
- Retroviruses (Coffin, Hughes, Varmus) - ncbi.nlm.nih.gov
- Reverse Transcriptase and Retroviral DNA - ncbi.nlm.nih.gov
- Retroviral reverse transcriptases review - pmc.ncbi.nlm.nih.gov
- A Brief Chronicle of Retrovirology - ncbi.nlm.nih.gov
